Suzhou Ribo Life Science Co. Ltd. Adopts ArisGlobal’s LifeSphere® MultiVigilance to Advance Clinical Trial Data Management
Innovative R&D company chooses LifeSphere by ArisGlobal to further develop its security capabilities
MIAMI, November 1, 2021 / PRNewswire / – ArisGlobal, the leading provider of life sciences software that automates basic drug development with its LifeSphere end-to-end drug development technology platformÂ® today announced its partnership with Suzhou Ribo Life Science Co., Ltd., an innovative R&D company dedicated to the development of nucleic acid-based drugs and related products based on RNA interference technology (RNAi). Ribo will leverage ArisGlobal’s LifeSphere Multivigilance in English and Chinese to manage safety data and meet regulatory requirements as products move into clinical trials.
“Clinical trials continue to generate large amounts of safety data for new products, and useful information is essential to bring products to market safely,” said Beena wood, vice president of security for ArisGlobal. âAs Ribo works with a multitude of oligonucleotide therapy R&D pipelines, LifeSphere Multivigilance can provide data models to connect siled datasets in global markets and combine them into a valuable data web. “
LifeSphere Multivigilance is a program in the LifeSphere family of security products. It is an end-to-end automated system that helps pharmacovigilance teams save time and effort, ensure future-proof compliance, and maintain alignment of global teams. The platform uses AI to improve workflow efficiency and offers 100% compliance with current and future regulatory requirements.
âAs Ribo continues to introduce innovative products into the clinical trial phase globally, we had to select an equally innovative security system with stable performance and strong data management capabilities,â said Jing-fu, vice-president of Ribo. âWe have confidence in the ArisGlobal products, and I believe our partnership will propel us forward as we bring more products to clinical trials in China and internationally. “
The news comes after ArisGlobal presented its signature Breakthrough2021 conference with key discussions on security, AI automation and adoption, and data, as well as the 2021 State of the World report. industry for life science R&D technology.
To learn more about ArisGlobal, please visit, www.arisglobal.com.
ArisGlobal is transforming the way today’s most successful life science companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphereÂ®, integrates our proprietary cognitive computing engine to automate all essential functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective spanning over 30 years, LifeSphereÂ® is a unified platform that improves efficiency, ensures compliance, delivers actionable insights and lowers total cost of ownership through a multi-tenant SaaS architecture.
Based at United States, ArisGlobal has regional offices in Europe, India, Japan and China. For more updates, follow ArisGlobal on LinkedIn and Twitter.
About Suzhou Ribo Life Science Co., LTD.
Suzhou Ribo Life Science Co., Ltd. is an innovative R&D company dedicated to the development of nucleic acid-based drugs and related products based on RNA interference (RNAi) technology. Thanks to its innovative R&D capabilities, Ribo has built a strong R&D pipeline with numerous drug products at different stages, aimed at contributing to the treatment of serious diseases affecting the Chinese population. Ribo has also built a solid foundation in liquid phase nucleic acid synthesis technology and the manufacture of nucleic acid based drugs. The founders of Ribo include some of the from China most renowned scientists in the field of RNAi technology. Ribo received the award for the first innovative team in Jiangsu China. Ribo is headquartered in Kunshan, Jiangsu Province and has a subsidiary in Beijing. For more information, please visit www.ribolia.com.
Logo – https://mma.prnewswire.com/media/1510670/ArisGlobal_Logo.jpg